succinobucol has been researched along with 2-tert-butylhydroquinone in 1 studies
| Studies (succinobucol) | Trials (succinobucol) | Recent Studies (post-2010) (succinobucol) | Studies (2-tert-butylhydroquinone) | Trials (2-tert-butylhydroquinone) | Recent Studies (post-2010) (2-tert-butylhydroquinone) |
|---|---|---|---|---|---|
| 53 | 5 | 16 | 633 | 2 | 300 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Braga, AL; Colle, D; de Bem, AF; Engel, DF; Farina, M; Godoi, M; Hartwig, JM; Santos, DB | 1 |
1 other study(ies) available for succinobucol and 2-tert-butylhydroquinone
| Article | Year |
|---|---|
Succinobucol, a Lipid-Lowering Drug, Protects Against 3-Nitropropionic Acid-Induced Mitochondrial Dysfunction and Oxidative Stress in SH-SY5Y Cells via Upregulation of Glutathione Levels and Glutamate Cysteine Ligase Activity.
Topics: Buthionine Sulfoximine; Cell Death; Cell Line, Tumor; Cell Survival; Glutamate-Cysteine Ligase; Glutathione; Glutathione Peroxidase; Humans; Hydroquinones; Hypolipidemic Agents; Mitochondria; Nitro Compounds; Oxidative Stress; Probucol; Propionates; Protective Agents; RNA, Messenger; Time Factors; Up-Regulation | 2016 |